After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty
The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC.
Zymergen’s rise began in April 2021 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
